Compare Amphastar Pharmaceuticals Inc (AMPH) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.9. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | PDBC | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $18.91 |
52-Week Low | $16.87 | $12.90 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
PDBC, an ETF tracking diversified commodities, trades at $17.25, up 0.12% with a bearish technical signal. Recent news highlights institutional inflows, such as Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (Defense World, 2026-07-19), and a Seeking Alpha downgrade to hold due to weakening commodity momentum (2026-06-11). The ETF has outperformed the S&P 500 by nearly 10 percentage points since March 2024 but faces headwinds from oil price declines and geopolitical tensions.
Outlook is mixed: commodities offer inflation hedging potential, with PDBC surging 50% amid supply disruptions (24/7 Wall Street, 2026-05-11), but risks include a potential 'super-squeeze' from Middle East conflicts (HSBC via 24/7 Wall Street, 2026-07-24) and tax-related complexities. Investors should weigh diversification benefits against volatile commodity cycles and roll costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
